WO2004041234A1 - Topical anhydrous delivery system for antioxidants - Google Patents
Topical anhydrous delivery system for antioxidants Download PDFInfo
- Publication number
- WO2004041234A1 WO2004041234A1 PCT/EP2003/011846 EP0311846W WO2004041234A1 WO 2004041234 A1 WO2004041234 A1 WO 2004041234A1 EP 0311846 W EP0311846 W EP 0311846W WO 2004041234 A1 WO2004041234 A1 WO 2004041234A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anhydrous
- weight
- composition according
- antioxidant
- preceeding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/31—Anhydrous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- This invention relates to novel compositions including but not limited to cosmetic compositions and/or therapeutic and/or prophylactic novel anhydrous delivery systems of cosmetic and/or pharmaceutical ingredients, and especially those including low molecular-weight hydrolysable tannins ( ⁇ 1,000) found in extracts of Phyllanthus emblica (hereinafter PE extracts), and processes for producing such compositions.
- PE extracts provide significant skin care benefits, including, for example, skin-lightening or whitening effects and/or anti-oxidant effects and/or skin appearance regulating effects.
- the present invention is applicable to all types of extracts of Phyllanthus emblica.
- compositions are disclosed which are prepared by merely pressing the fruit or obtaining a dilute-alcoholic extract. Both the extracts obtained by pressing and the extracts obtained by alcoholic maceration may then be concentrated at a moderate temperature under reduced pressure, preferably less than 50°C, then optionally brought to the dry state by freeze-drying or any other method under reduced pressure and at a temperature that is lower than 50°C so as to avoid degrading the active ingredients of the fruit.
- examples 3, 6 and 8 of the French patent 2730408 illustrate the manufacture and uses of extracts based on Phyllantus emblica.
- An antioxidant blend consisting essentially of, by weight, (I) and (2) about 35-55% of the gallic/ellagic acid derivatives of 2-keto-glucono- ⁇ - lactone; (3) about 4-15% of 2,3-di-O-galloyl-4, 6-(S)- hexahydroxydiphenoylgluconic acid; (4) about 10-20% of 2,3,4,6-bis-(S)- hexahydroxydiphenoyl-D-glucose; (5) about 5-15% of 3',4',5,7- tetrahydroxyflavone-3-O-rhamnoglucoside; and (6) about 10-30% of tannoids of gallic/ellagic acid.
- the common names of the enumerated compounds are (1) and (2) Emblicanin A and Emblicanin B, (3) Punigluconin, (4) Pedunculagin and (5) Rutin.
- a preferred antioxidant composition used in the present invention comprises a modification of the CAPROS composition, comprising a standardized extract of low molecular weight ( ⁇ 1000) hydroiyzable tannins, over 40%, preferably 50-80% w/w of Emblicanin A, Emblicanin B, Pedunculagin, and Punigluconin with low levels ( ⁇ 1 %, w/w) of total flavonoids whereby the resultant products of the invention can be made into elegant white to off-white formulations.
- Such a composition is discussed with greater specificity in pages 28-30 of the August 2001 issue of Soap, Perfumery and Cosmetics, the article having the title Ingredients/Emblica, Bearing Fruit, by Ratan K. Chaudhuri. In the article that there is no mention, however, of any flavonoids much less the maximum acceptable amounts in the composition.
- the total flavonoids are maintained at a level which does not impair the desired color, e.g. generally, by weight, less than about 1.0%, preferably less than about 0.8%, and even more preferably less than about 0.6%.
- the desired concentrations of the Rutin species of flavonoids (3',4',5',7- tetrahydroxyflavone-3-O-rhamnoglucoside) in the standardized extract are less than 1.0%, less than 0.01 %, less than 0.001% and less than 0.0001%, with a value of 0.01 to 0.001% being particularly preferred.
- the most preferred concentrations of the components are on a percent by weight basis of the total dried extract:
- the standardized composition may exhibit average percentage deviations from these preferred values of:
- the antioxidant composition can be obtained by removal of the total flavonoids by reversed-phase column chromatography or HPLC using a solvent system of acetonitrile, water/phosphoric acid (20/80/1) or other solvent combinations as they elute faster than the low molecular-weight tannins. Also, by selection of geographical location, the Phyllanthus emblica fruit extract may provide a substantially lower level of the total flavonoids ( ⁇ 1.0%). It has been observed that medium-sized fruits collected from some parts of eastern India, during October-November, after water extraction and drying, yielded the preferred antioxidant composition as a powder with the desired low content of total flavonoids. Accordingly, by analyzing the total flavonoids content of extracts and selecting such extracts that contain the desired low content of total flavonoids, it is possible to prepare a standardized extract.
- flavonoids include a family of compounds which exhibit a peak at 350 nm when analyzed by a UV spectrometer.
- flavonoids include but are not limited to flavonols and flavones, a species thereof being Rutin as discussed above.
- a substantially water- soluble (over 95% by weight) extract of Phyllanthus Emblica comprising less than 5% by weight of polymeric tannins, with substantially no black specks and at high levels, e.g. over 75% by weight of bio-active, low molecular-weight hydrolysable tannins having molecular weights below 1 ,000 is used.
- This extract can be obtained by an process which removes ologomeric and polymeric tannins.
- a suitable process comprises the following steps: 1 ) providing an extract of Phyllanthus Emblica either resulting from the original extract from the plant, or from a suspension of a powdered composition obtained after the extract is processed, e.g. after a drying step; 2) If necessary, physically separating the black specks and/or precursors thereof and/or polymeric tannins from the water-soluble components, for example by filtration with the use of a filter aid; 3) If desired, concentrating the resultant aqueous solution of the enriched composition of Emblica officinalis, for example to a dry powder.
- Aqueous formulations of PE extracts are described in the above- identified patents and applications, these formulations being generally made by introducing a minor amount of powdered PE extracts into an aqueous solution along with known excipients. Whereas these formulations are commercially acceptable, a discoloration of such solutions has been observed after prolonged storage. The cause of such discoloration is believed to be due to the fact that the PE extracts contain polyphenolic compounds which a re s usceptible to a erial oxidation on the one hand and hydrolysis on the other hand; however, Applicants do not wish to be bound by this explanation of the mechanism of discoloration.
- One aspect of the present invention therefore is to provide a delivery system which will inhibit or prevent discoloration, presumably by inhibiting or preventing such aerial oxidation and/or hydrolysis of active ingredients, PE extracts in particular.
- Other aspects of the invention are to provide a process for producing a final substantially anhydrous formulation and the resultant product.
- Still another aspect is a formulation that provides improved adhesion and skin-feel properties.
- formulations which are not based on water, but instead are based on a substantially anhydrous or non-aqueous vehicle so that the final formulation contains preferably less than 1 % by weight of water.
- the vehicle must be capable of dispersing the PE extracts with adjuvants if necessary. It is also preferred that the non-aqueous vehicle have an emollient function as well.
- Classes of vehicles to be used in the present invention include but are not limited to silicone fluids, organic esters and glycols.
- silicone vehicles include but are not limited to cyclomethicone, both the tetramer and the pentamer, hexamethyldisiloxane, phenyltrimethicone cross linked polymers of dimethicone and cyclomethicone (hereinafter "crosspolymer”) methylvinylsiloxanes, methylvinylsiloxane-dimethylsiloxane copolymers, dimethylvinylsiloxy-terminated dimethylpolysiloxanes, dimethylvinylsiloxy- terminated dimethylsiloxane-methylphenylsiloxane copolymers, dimethylvinylsiloxy-terminated dimethylsiloxane-diphenylsiloxane- methylvinylsiloxane copolymers, trimethylsiloxy-terminated dimethylsiloxane-methylbinylsiloxane copolymers, trimethylsiloxy-terminated dimethylsiloxan
- esters include but are not limited to cetearyl octanoate, caprylic/capric triglyceride, octylhydroxysterate, PPG-2 myristyl ether propionate, tentaerythrityl tetracaprylate/caprate, tentaerythrityl tetraisosterate, natural and synthetic jojoba oils, cetyl acetate, and acetylated lanolin alcohol.
- glycols include but are not limited to mono- or poly- alkylene glycols are contemplated, a non-limiting example being propylene glycol.
- the vehicle has emollient properties
- the content of the vehicle is sufficient, generally, about 20-80%, preferably 20-60% by weight of the completed formulation to achieve the desired dispersibility of the PE extracts.
- the content of PE extracts in the formulation is generally about from 0.05 to 10%, preferably 0.1-3% by weight, with the preferred minimum weight ratio of the content of the vehicle to the content of the PE extracts being about 20:3.
- Another aspect of this invention concerns the preferred addition of at least one structural and/or gelling agent.
- Such structural/gelling agents can be combined with the EP extracts to form a m ixture comprising the P E extract with the structural agent, and/or the gelling agent.
- the structural/gelling agent can be combined with the substantially anhydrous vehicle in order to form corresponding mixtures which thereafter can be combined with the PE extracts.
- the structural agent which provides firmness, structure, consistency and thermal stability to the product can be selected from subgeneric classes of materials which include but are not limited to natural, modified or unmodified waxes, mineral waxes, high melting point fatty alcohols, glycerol or glycol esters, polyethylene and polyethylene glycol polymers.
- Examples of the natural modified or unmodified waxes include but are not limited to beeswax, candelilla wax, carnauba wax, and hydrogenated castor wax.
- Examples of mineral waxes include but are not limited to ozokerite and ceresin.
- high melting fatty alcohols include but are not limited to cetyl alcohol and stearyl alcohol.
- glycerol or glycol esters examples include but are not limited to Croda Syncrowaxes, i.e. 18-36 glycol esters.
- polyethylene glycol polymers includes but is not limited to Carbowax Sentry 1000.
- the structural agents are incorporated in the final formulation at a level of about 5-50% by weight.
- gelling agents which are also used in an amount of 5-50% by weight of the final formulation, subgeneric classes include but are not limited to silicone elastomers, gelled natural and mineral oil systems and gelled mineral oil and polymer systems.
- silicone elastomers include but are not limited to cyclomethicone and dimethicone cross polymers e.g. Dow Corning 9040, polysilicone-11 mixtures, e.g. Gransil PM Gel, and Gransil DCM, and
- gelled natural and mineral oil systems include but are not limited to a mixture of canola oil and silica and corn starch, e.g.
- Vegelatum Clear a mixture of canola oil, soy bean germ extract, corn starch and silica, e.g. Vegelatum Equiline; gelled castor oil and rice bran oil
- gelled mineral oil and polymer systems include but are not limited to esters of hydrogenated polyisobutene, ethylene/propylene/styrene copolymers, and butylene/ethylene/styrene copolymers, e.g. Versagel M, ME, MC, MD, ME, MJ and MP (Penreco).
- polystyrene resin e.g. Indopol H-100.
- the total amount of the sum of the structural agent and gelling agent will be determined by the desired rheological properties of the final formulation. As a guideline, the total amount of the sum in the final formulations will be in the range 5-90% by weight.
- the substantially anhydrous delivery system of the present invention can be utilized for the incorporation of any PE-extract; however, the delivery system is particularly beneficial for the incorporation of the standardized extract described above and especially the commercial product EMBLICATM. It is also contemplated that the anhydrous delivery system of the present invention can be utilized for the incorporation of other active materials.
- Additional ingredients can be added to the formulation for their known functions, for example skin lightening agents, skin brightening agents, skin even-toning agents, anti-aging agents, sunscreen agents, and antiperspirant/deodorant agents, herbal products, vitamins, and medicaments. Since rheological properties of the final product will primarily be dependent on the nature and proportion of the vehicle and the structural and gelling agents of same, the formulator can tailor make the final formulation to the desired product, e.g. semi-solid or gel.
- antiperspirant agents include but are not limited to aluminum zirconium tetrachlorohydrex GLY (coordination complex of aluminium zirconium tetrachlorohydrate and glycerine)
- additives for skin feel and adhesion include but are not limited to bismuth oxychloride, Boron Nitride, PPG-3 myristyl ether, glyceryl laurate, PEG-40 castor oil and PEG-derivatives of fatty alcohols and mixtures thereof.
- bismuth oxychloride in particular, it has been discovered that by the addition of same, important advantageous properties are imparted to the composition.
- the appearance and consistency of the final product may be improved considerably by the addition of generally about 0.5 to 20%, preferably 2 to 10% by weight, of powdered bismuth oxychloride pigment (e.g., Biron ® LF-2000).
- the formulated product with the pigment is whiter, has a more substantial appearance, and offers a much drier, silkier skin feel, than the same product without this pigment. Adhesion to the skin is also improved with the addition of this pigment.
- a list of some presently commercially available bismuth oxychlorides is given below.
- Iridescent bismuth oxychloride coated mica pigments are also contemplated. Whereas all bismuth oxychloride pigments will provide advantageous properties, the preferred pigments are Biron® LF-2000 and Biron® MTU.
- Biron ® LF-2000 is a white pigment having particle size (determined by Laserbeam Diffraction; Malvern 2000) ⁇ 35 ⁇ m (80% within range) and 8.0 - 20.0 ⁇ m (D50: median size) which offers excellent skin feel, and adds some luster to the final product
- Biron ® MTU is a white pigment having particle size 2.0 - 35.0 ⁇ m (80% within range) and 12.0 -18.0 ⁇ m (D50: median range) which also offers improved skin feel and a more matte look to the product on the skin
- Bismuth oxychloride can also be included in the invention, such as, a range of Bismuth oxychloride products available from Engelhard. These are:
- Mearlite ® GLS Some light-stability, lustrous
- compositions without PE include color cosmetic products such as lipsticks, lip glosses, and lip balms.
- color cosmetic products such as lipsticks, lip glosses, and lip balms.
- Anhydrous cream-to- powder foundations, creamy eye shadow, and blushers may also benefit from such a delivery system.
- Hair pomades, shaping balms, and molding waxes may also be formulated with this delivery system, as can various anhydrous ointment systems for such applications as diaper rash, muscle aches, and burns.
- PE because of its antioxidant, anti-aging, skin lightening and skin even toning properties will impart improved properties to all of the products.
- antioxidants may be incorporated in the system which include mixtures of antioxidants suitable for use in the cosmetic formulations.
- Known and commercial mixtures are, for example, mixtures comprising, as active ingredients, lecithin, L-(+)-ascorbyl palminate and citric acid (e.g. Oxynex ® AP), natural tocopherols, L-(+)-ascorbyl palmitate, L-(+)-ascorbic acid and citric acid (e.g. Oxynex ® K LIQUID), tocopherol extracts from natural sources, L-(+)-ascorbyl palmitate, L-(+)-ascorbic acid and citric acid (e.g.
- Oxynex ® L LIQUID D L- ⁇ -tocopherol, L -(+)-ascorbyl palmitate, citric acid and lecithin (e.g. Oxynex ® LM) or butylhydroxytoluene (BHT), L-(+)- ascorbyl palmitate and citric acid (e.g. Oxynex ® 2004).
- the formulations according to the invention can comprise vitamins as further ingredients.
- vitamins and vitamin derivatives chosen from vitamin A, vitamin A propionate, vitamin A palmitate, vitamin A acetate, retinol, vitamin B, thiamine chloride hydrochloride (vitamin B1), riboflavin (vitamin B2) nicotinamide, vitamin C ( ascorbic acid), vitamin D , ergocalciferol (vitamin D2), vitamin E, DL-tocopherol, tocopherol E acetage, tocopherol hydrogen-succinate, vitamin K1 , esculin (vitamin P active ingredient), thiamine (vitamin B1) nicotinic acid (niacin), pyridoxine, pyridoxal, pyridoaxmine, (vitamin B 6), p anthothenic acid, biotin, folic acid and cobalamine (vitamin B12) are present in the cosmetic formulations according to the invention, particularly preferably vitamin A palmitate, vitamin C,
- compositions of the present invention may also comprise one or more organic sunscreens.
- Suitable sunscreens can have UVA absorbing properties, UVB absorbing properties or a mixture thereof.
- the exact amount of the sunscreen active will vary depending upon the desired sun protection factor, i.e. the "SPF" of the composition as well as the desired level of UVA protection.
- the compositions of the present invention preferably comprise an SPF of at least 10, preferably at least 15.
- SPF is a commonly used measure of photoprotection of a sunscreen against erythema.
- the SPF is defined as a ratio of the ultraviolet energy required to produce minimal erythema on protected skin to that required to products the same minimal erythema on unprotected skin in the same individual. See Federal Register, 43, No 166, pp.
- compositions of the present invention preferably comprise from about 2% to about 25%>, more typically from about 4% to about 15%, by weight, of organic sunscreen.
- Suitable sunscreens include, but are not limited to, those found in the CTFA International Cosmetic Ingredient Dictionary and Handbook, 7.sup.th edition, volume 2 pp. 1672, edited by Wenninger and McEwen (The Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, D.C., 1997).
- compositions of the present invention preferably comprise a UVA absorbing sunscreen actives that absorb UV radiation having a wavelength of from about 320 nm to about 400 nm.
- Suitable UVA absorbing sunscreen actives are selected from dibenzoylmethane derivatives, anthranilate derivatives such as methylanthranilate and homomethyl, 1-N-acetylanthranilate, and mixtures thereof. Examples of dibenzoylmethane sunscreen actives are described in U.S. Patent No. 4,387,089; a nd i n S unscreens: D evelopment, Evaluation, a nd Regulatory Aspects, Second edition, edited by N.J. Lowe and N.A. Shaath, Marcel Dekker, Inc. (1997).
- the UVA absorbing sunscreen active is preferably present in an amount to provide broad-spectrum UVA protection either independently, or in combination with, other UV protective actives that may be present in the composition.
- Preferred UVA sunscreen actives are dibenzoylmethane sunscreen actives and their derivatives. They i nclude, b ut a re n ot I imited t o, t hose selected from 2-methyldibenzoylmethane, 4-methyldibenzoylmethane, 4- isopropyldibenzoylmethane, 4-tert-butyldibenzoylmethane, 2, 4- dimethyldibenzoylmethane, 2, 5-dimethyldibenzoylmethane, 4, 4'- diisopropylbenzoylmethane, 4-(1 ,1-dimethylethyl)-4'-methoxydibenzoyl methane, 2-methyl-5-isopropyl-4'-methoxydibenzoylmethane, 2-methyl-5- tert-butyl-4'-methoxy-dibenzoylmethane, 2, 4-dimethyl-4'
- dibenzoyl sunscreen actives include those selected from 4-(1, 1-dimethylethyl)-4'- methoxydibenzoylmethane, 4-isopropyldibenzoylmethane, and mixtures thereof.
- a more preferred sunscreen active is 4-(1, 1-dimethylethyl)-4'- methoxydibenzoylmethane also known as butyl methoxydibenzoylmethane or Avobenzone.
- the compositions of the present invention preferably further comprise a UVB sunscreen active that absorbs UV radiation having a wavelength of from about 290 nm to about 320 nm.
- the compositions preferably comprise an amount of the UVB sunscreen active that is safe and effective to provide UVB protection either independently, or in combination with, other UV protective actives that may be present in the compositions.
- the compositions preferably comprise from about 1% to about 15%, more preferably from about 1% to about 12%, of UVB absorbing organic sunscreen.
- UVB sunscreen actives are suitable for use herein.
- a list of currently approved sunscreens can be found in Organic Sunscreens published by R. Chaudhuri et al. in The Chemistry and Manufacture of Cosmetics, Vol. Ill, pages 627-644 (2002).
- Preferred UVB sunscreen actives are3 selected from 2-ethylhexyl-2-cyano-3, 3- diphenylacrylate (referred to as octocrylene), Homomenthyl salicylate, 2- phenyl-benzimidazoie-5-suIphonic acid (PBSA), cinnamates and their derivatives such as 2-ethylhexyl-p-methoxycinnamate and octyl-p- methoxycinnamate, TEA salicylate, octyidimethyl PABA, camphor derivatives and their derivatives, and mixtures thereof. Salt and acid neutralized forms of the acidic sunscreens are also useful herein.
- organic sunscreen salts such as PBSA
- PBSA fatty alcohols or nonionic surfactants
- An agent may also be added to any of the compositions useful in the present invention to stabilize the UVA sunscreen to prevent it from photo- degrading on exposure to UV radiation and thereby maintaining its UVA protection efficacy.
- Wide ranges of compounds have been cited as providing these stabilizing properties and should be chosen to compliment both the UVA sunscreen and the composition as a whole.
- Suitable stabilizing agents include, but are n ot I imited to, those d escribed i n U .S. Patent N os. 5,972,316; 5,968,485; 5,935,556; 5,827,508 and Patent WO 00/06110.
- Preferred examples of stabilizing agents for use in the present invention include 2-ethylhexyl-2-cyano-3, 3-diphenylacrylate (referred to as octocrylene), ethyl-2-cyano-3, 3-diphenylacrylate, 2-ethylhexyl-3, 3- diphenylacrylate, ethyi-3, 3-bis (4-methoxypheny! acrylate, and mixtures thereof.
- t he f inal formulation on a weight basis comprises in general about 20-80%, preferably 20-60% of a substantially anhydrous liquid vehicle, a total of about 5 to about 90% of a structural and/or gelling agent, and 0.05-10%, preferably 0.1-3% of a PE extract, especially the extract having the trademark EMBLICA.
- Other components, especially bismuth oxychloride, can be incorporated in percentages that function for their intended purpose.
- the preferred combination of ingredients is 30-40% o silicone oils (such as,
- the first step comprises blending a mixture of about 5 to 80% of a vehicle and 5 to 90 of a structural or gelling agent with sufficient heat, e.g. a temperature of about 60 to 90°C and mixing until a clear and uniform mixture is obtained.
- the PE extract is mixed with a minor amount of, e.g. 1 to 20% of the same vehicle used in the first step together with a minor amount 1 to 30% of a structural and/or gelling agent.
- This subsequent step is important insofar as the mixture should be blended with sufficient heat but preferably below 60°C until it is relatively smooth and contains no visible lumps.
- the product from this subsequent step is then mixed with that of the first step containing the major amounts of vehicle and structural/gelling agents, the mixing being conducted at preferably below 60°C, for example 40-50°C so as to avoid a ny d ecomposition of the P E extract.
- the ingredients in the first step can be heated to a higher temperature which will facilitate mixing, and the resultant mixture then can be cooled to below 60°C before mixing with the minor composition containing the PE extract and the minor amounts of vehicle and structural/gelling agents.
- an antiperspirant agent can be added to the product of the first step a nd then b lended therein.
- I n such a p rocess, the s ubsequent step mentioned above, would be a third step after the antiperspirant agent is blended and the resultant mixture is cooled to below 60°C.
- Final product can be packaged in any suitable container for daily use for multiple applications. Also, this product can be provided as a single dose application, for example in gelatin capsules.
- EXAMPLE 1 ANHYDROUS DELIVERY SYSTEM for EMBLICA TM WITHOUT BISMUTH OXYCHLORIDE
- Blend ingredients in Phase A heat with mixing at about 70 ⁇ 80°C until clear and uniform.
- Blend ingredients in Phase B separately at a temperature below 60°C, e.g. room temperature; the mixture should be smooth and contain no lumps.
- Cool Phase A to about 60°C and add Phase B with mixing. When the mixture is uniform it may be packaged.
- Biron ® LF-2000 whitens the gel and allows for greater skin adhesion and a much smoother, silkier skin feel to the final product.
- These benefits can also be obtained in other systems, as illustrated in Examples 3 and 4 below.
- the viscosity of the final product may be varied, from a stable solid, as in Examples 1 , 2 and 3, to a flowable gel, as in Example 4.
- Biron ® LF-2000 adds whiteness, a smoother skin feel, and greater skin adhesion to the final product.
- EXAMPLE 2 ANTIPERSPIRANT with EMBLICA TM
- EXAMPLE 10 ANHYDROUS SYSTEM WITH SUNSCREENS
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/534,034 US20060057169A1 (en) | 2002-07-15 | 2003-10-24 | Topical anhydrous delivery system for antioxidants |
JP2005502100A JP2006511597A (en) | 2002-11-07 | 2003-10-24 | Topical anhydrous delivery system for antioxidants |
EP03810406A EP1558207A1 (en) | 2002-11-07 | 2003-10-24 | Topical anhydrous delivery system for antioxidants |
AU2003276180A AU2003276180A1 (en) | 2002-11-07 | 2003-10-24 | Topical anhydrous delivery system for antioxidants |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42431602P | 2002-11-07 | 2002-11-07 | |
US60/424,316 | 2002-11-07 | ||
US10/616,494 US20040076699A1 (en) | 2002-07-15 | 2003-07-10 | Topical anhydrous delivery system |
US10/616,494 | 2003-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004041234A1 true WO2004041234A1 (en) | 2004-05-21 |
Family
ID=32314531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/011846 WO2004041234A1 (en) | 2002-07-15 | 2003-10-24 | Topical anhydrous delivery system for antioxidants |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040076699A1 (en) |
EP (1) | EP1558207A1 (en) |
JP (1) | JP2006511597A (en) |
AU (1) | AU2003276180A1 (en) |
WO (1) | WO2004041234A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025532A1 (en) * | 2003-09-12 | 2005-03-24 | Merck Patent Gmbh | Enriched aqueous components of emblica officinalis |
WO2006009993A1 (en) * | 2004-06-21 | 2006-01-26 | The Procter & Gamble Company | Antiperspirant compositions comprising ozokerite |
CZ296773B6 (en) * | 2004-02-16 | 2006-06-14 | Avicenna Company, S. R. O. | Vegetable preparation exhibiting antioxidant activity |
WO2006071404A1 (en) * | 2004-12-29 | 2006-07-06 | Colgate-Palmolive Company | Oxidation resistant dentifrice compositions |
WO2011010041A2 (en) | 2009-07-20 | 2011-01-27 | L'oreal | Emulsion containing a bismuth oxychloride dispersion |
WO2017037716A2 (en) | 2015-09-03 | 2017-03-09 | Tagra Biotechnologies Ltd. | Microcapsules encapsulating a reflective agent |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7033614B2 (en) * | 2003-08-27 | 2006-04-25 | Emd Chemicals, Inc. (Previously Em Industries) | Bismuth oxychloride compositions and methods of rinsing |
EP1591099A3 (en) * | 2004-04-28 | 2005-11-09 | MERCK PATENT GmbH | Methods for stabilizing ingredients within cosmetics, personal care and household products |
US8017136B2 (en) * | 2004-05-24 | 2011-09-13 | The Procter & Gamble Company | Shiny foundation |
US20060263321A1 (en) * | 2005-05-17 | 2006-11-23 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using personal care compositions comprising diethylhexyl syringylidene malonate |
FR2902002B1 (en) * | 2006-06-12 | 2010-08-27 | Lvmh Rech | FREE ANTI-RADICAL COSMETIC COMPOSITION |
WO2008035353A2 (en) * | 2006-09-20 | 2008-03-27 | Benny Benny Antony | Polyphenol blend having superior transdermal delivery properties |
WO2008119428A1 (en) * | 2007-04-03 | 2008-10-09 | Merck Patent Gmbh | Photostable compositions |
ES2950993T3 (en) | 2008-11-17 | 2023-10-17 | Oreal | Cosmetic procedure for treating human perspiration using particles of an expanded amorphous mineral material; compositions |
PT106679B (en) * | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | TOPICAL FORMULATIONS OF TETRACYCLINES, THEIR PREPARATION AND USES |
DE102014213155A1 (en) * | 2014-07-07 | 2016-01-07 | Henkel Ag & Co. Kgaa | Silicone gel with a dry feel |
WO2017036542A1 (en) * | 2015-09-03 | 2017-03-09 | L'oreal | Anhydrous composition for caring for and/or making up keratin materials comprising microcapsules encapsulating an oily dispersion of at least one reflective agent |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345571A1 (en) * | 1988-06-09 | 1989-12-13 | Singh-Verma, Shyam Bir, Dr. | Plant extract composition for cosmetical use |
WO2000002535A1 (en) * | 1998-07-10 | 2000-01-20 | Shaklee Corporation | Improved stable topical ascorbic acid compositions |
US6124268A (en) * | 1999-02-17 | 2000-09-26 | Natreon Inc. | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
US6261605B1 (en) * | 1996-12-28 | 2001-07-17 | Shyam B. Singh-Verma | Cosmetic preparations containing extracts from phyllanthus emblica and centella asiatica and/or bacopa monnieri |
US6362167B1 (en) * | 1999-02-17 | 2002-03-26 | Natreon Inc. | Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3822141A (en) * | 1970-10-08 | 1974-07-02 | Whittaker Corp | Coated pearlescent product |
FR2534138B1 (en) * | 1982-10-12 | 1985-06-07 | Oreal | EYESHADOW |
US6103250A (en) * | 1999-07-06 | 2000-08-15 | Revlon Consumer Products Corporation | Anhydrous cosmetic compositions containing emulsifying siloxane elastomer |
US6475500B2 (en) * | 2000-07-10 | 2002-11-05 | The Procter & Gamble Company | Anhydrous cosmetic compositions |
US6649150B2 (en) * | 2002-04-11 | 2003-11-18 | Em Industries | Skin-lightening |
-
2003
- 2003-07-10 US US10/616,494 patent/US20040076699A1/en not_active Abandoned
- 2003-10-24 AU AU2003276180A patent/AU2003276180A1/en not_active Abandoned
- 2003-10-24 JP JP2005502100A patent/JP2006511597A/en active Pending
- 2003-10-24 EP EP03810406A patent/EP1558207A1/en not_active Withdrawn
- 2003-10-24 WO PCT/EP2003/011846 patent/WO2004041234A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345571A1 (en) * | 1988-06-09 | 1989-12-13 | Singh-Verma, Shyam Bir, Dr. | Plant extract composition for cosmetical use |
US6261605B1 (en) * | 1996-12-28 | 2001-07-17 | Shyam B. Singh-Verma | Cosmetic preparations containing extracts from phyllanthus emblica and centella asiatica and/or bacopa monnieri |
WO2000002535A1 (en) * | 1998-07-10 | 2000-01-20 | Shaklee Corporation | Improved stable topical ascorbic acid compositions |
US6124268A (en) * | 1999-02-17 | 2000-09-26 | Natreon Inc. | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
US6362167B1 (en) * | 1999-02-17 | 2002-03-26 | Natreon Inc. | Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025532A1 (en) * | 2003-09-12 | 2005-03-24 | Merck Patent Gmbh | Enriched aqueous components of emblica officinalis |
CZ296773B6 (en) * | 2004-02-16 | 2006-06-14 | Avicenna Company, S. R. O. | Vegetable preparation exhibiting antioxidant activity |
WO2006009993A1 (en) * | 2004-06-21 | 2006-01-26 | The Procter & Gamble Company | Antiperspirant compositions comprising ozokerite |
WO2006071404A1 (en) * | 2004-12-29 | 2006-07-06 | Colgate-Palmolive Company | Oxidation resistant dentifrice compositions |
AU2005322462B2 (en) * | 2004-12-29 | 2009-11-19 | Colgate-Palmolive Company | Oxidation resistant dentifrice compositions |
WO2011010041A2 (en) | 2009-07-20 | 2011-01-27 | L'oreal | Emulsion containing a bismuth oxychloride dispersion |
EP2826459A1 (en) | 2009-07-20 | 2015-01-21 | L'oreal | Emulsion containing a dispersion of bismuth oxychloride |
EP2826460A1 (en) | 2009-07-20 | 2015-01-21 | L'oreal | Emulsion containing a dispersion of bismuth oxychloride |
WO2017037716A2 (en) | 2015-09-03 | 2017-03-09 | Tagra Biotechnologies Ltd. | Microcapsules encapsulating a reflective agent |
US11065593B2 (en) | 2015-09-03 | 2021-07-20 | Tagra Biotechnologies Ltd. | Microcapsules encapsulating a reflective agent |
Also Published As
Publication number | Publication date |
---|---|
AU2003276180A1 (en) | 2004-06-07 |
US20040076699A1 (en) | 2004-04-22 |
EP1558207A1 (en) | 2005-08-03 |
JP2006511597A (en) | 2006-04-06 |
AU2003276180A8 (en) | 2004-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004041234A1 (en) | Topical anhydrous delivery system for antioxidants | |
CA2144676C (en) | Solid lipophilic composition and process for its preparation | |
US6048517A (en) | High SPF sunscreen formulations | |
US20050196361A1 (en) | Non endocrine disrupting cytoprotective UV radiation resistant composition | |
KR20110021853A (en) | Compositions for topical application comprising microencapsulated colorants | |
CA2709891A1 (en) | Topical compositions containing citrus jabara extract | |
EP1109528B1 (en) | Self-tanning compositions containing dha and propolis extract | |
EP2627306B1 (en) | A sunscreen composition | |
WO2005065136A2 (en) | Oil in silicone emulsions and compositions containing same | |
US20160008256A1 (en) | A photoprotective personal care composition | |
JP2020526540A (en) | Light and aesthetic sunscreen composition | |
US6080430A (en) | Powder coated with sparingly soluble ultraviolet absorber | |
US20080102045A1 (en) | Topical preparations containing antioxidant extracts of broccoli, green tea, and red tea | |
JP2007262008A (en) | Ultraviolet absorber composed of arbutin caffeic acid ester and cosmetic containing the same | |
US20060057169A1 (en) | Topical anhydrous delivery system for antioxidants | |
US9452125B2 (en) | Self-tanning compositions having reduced maillard reaction malodor | |
DE102008004665B4 (en) | Cosmetic composition with anti-aging effect | |
JPH0525853B2 (en) | ||
KR102093201B1 (en) | A cosmetic composition for sun protection using karanja oil and Tamanu oil | |
KR102354352B1 (en) | Oil-in- water cosmetic composition comprising physical sunscreen | |
CN115475105A (en) | Water-in-oil type solid cosmetic | |
US20230310290A1 (en) | Sunscreen or daily care composition comprising micronized tris-biphenyl triazine | |
KR20210036783A (en) | Sunscreen composition containing surface modified cerium oxide particles by polyhydroxystearic acid and method of preparing the same | |
EP4208148A1 (en) | Sunscreen or daily care composition comprising micronized methylene bis-benzotriazolyl tetramethylbutylphenol | |
WO2021092667A1 (en) | Photoprotective compositions, photoprotective formulations including photoprotective compositions, preparation methods and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003810406 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006057169 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10534034 Country of ref document: US Ref document number: 2005502100 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003810406 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10534034 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003810406 Country of ref document: EP |